Physician profile
Jackson D Wright
NPI 1225408461
$4,860.73
in general payments reported to CMS, 2019-2025
33 companies · $1,538 in 2025
The $1,538 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $342 · 2022: $679 · 2023: $926 · 2024: $1,374 · 2025: $1,538.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,839.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,839.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,025.70 | 2021-2025 | |
| Viiv Healthcare Company | $953.31 | 2022-2025 | Dovato, Apretude, Cabenuva |
| Gilead Sciences, INC. | $455.91 | 2023-2025 | Biktarvy |
| Merck Sharp & Dohme LLC | $424.92 | 2021-2025 | Pifeltro, Delstrigo, Capvaxive |
| Bayer Healthcare Pharmaceuticals INC. | $268.61 | 2021-2025 | |
| Glaxosmithkline, LLC. | $253.42 | 2023-2025 | Arexvy, Shingrix, Bexsero |
| Pfizer INC. | $224.69 | 2022-2025 | |
| Novo Nordisk INC | $205.74 | 2021-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $122.41 | 2022-2025 | Breztri, Farxiga |
| Lilly USA, LLC | $99.48 | 2021-2025 | Mounjaro |
| Amgen INC. | $94.36 | 2021-2025 | Repatha, Krystexxa, Otezla |
| Janssen Pharmaceuticals, INC | $78.80 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.72 | 2021-2025 | Jardiance, Synjardy |
| Idorsia Pharmaceuticals US INC | $57.24 | 2022-2023 | Quviviq |
| Sanofi Pasteur INC. | $55.44 | 2022-2023 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $51.73 | 2024 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.17 | 2021-2025 | Xifaxan |
| Exact Sciences Corporation | $40.80 | 2025 | The Cologuard Plus Collection Kit |
| Edwards Lifesciences Corporation | $33.33 | 2022-2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Cranial Technologies, INC | $31.55 | 2021-2023 | Doc Band |
| Teva Pharmaceuticals USA, INC. | $31.10 | 2024 | Austedo Xr |
| Xeris Pharmaceuticals, INC. | $30.08 | 2022-2025 | Gvoke Hypopen |
| Tactile Systems Technology INC | $25.39 | 2025 | Flexitouch Plus, Nimbl |
| Supernus Pharmaceuticals, INC. | $23.17 | 2025 | Qelbree |
| Vanda Pharmaceuticals INC. | $21.69 | 2024 | Fanapt |
| Seqirus USA INC | $20.66 | 2025 | Flucelvax, Fluad |
| Ironshore Pharmaceuticals INC. | $19.24 | 2023 | Jornay Pm |
| Lundbeck LLC | $17.35 | 2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $16.79 | 2023 | Eliquis |
| Janssen Biotech, INC. | $16.50 | 2023 | Symtuza |
| Sobi, INC | $13.09 | 2023 | |
| Sanofi-Aventis U.S. LLC | $13.08 | 2024 | |
| Phathom Pharmaceuticals, INC. | $9.26 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jackson Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.